Cost-effectiveness of transesophageal echocardiography to determine the duration of therapy for intravascular catheter-associated Staphylococcus aureus bacteremia

Annals of Internal Medicine

Volumn 130, Issue 10, 1999, Pages 810-820

  Rosen, Allison B ^a   Fowler Jr , Vance G ^a   Corey, G Ralph ^a   Downs, Stephen M ^b   Biddle, Andrea K ^b   Li, Jennifer ^a   Jollis, James G ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT;

ANTIBIOTIC THERAPY; ARTICLE; BACTEREMIA; BACTERIAL ENDOCARDITIS; CATHETER INFECTION; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; HUMAN; INTRAVASCULAR CATHETER; LONG TERM CARE; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; STAPHYLOCOCCUS AUREUS; TRANSESOPHAGEAL ECHOCARDIOGRAPHY;

EID: 0032949454     PISSN: 00034819     EISSN: None     Source Type: Journal    
DOI: 10.7326/0003-4819-130-10-199905180-00004     Document Type: Article

References (108)

1. Maki DG. Nosocomial bacteremia. An epidemiologic overview. Am J Med. 1981;70:719-32.
2. Raad II, Bodey GP. Infectious complications of indwelling vascular catheters. Clin Infect Dis. 1992;15:197-208.
3. Steinberg JP, Clark CC, Hackman BO. Nosocomial and community-acquired Staphylococcus aureus bacteremias from 1980 to 1993: impact of intravascular devices and methicillin resistance. Clin Infect Dis. 1996;23:255-9.
4. Watanakunakorn C, Tan JS, Phair JP. Some salient features of Staphylococcus aureus endocarditis. Am J Med. 1973;54:473-81.
5. Mirimanoff RO, Glauser MP. Endocarditis during Staphylococcus aureus septicemia in a population of non-drug addicts. Arch Intern Med. 1982;142: 1311-3.
6. Chambers HF, Korzeniowski OM, Sande MA. Staphylococcus aureus endocarditis: clinical manifestations in addicts and nonaddicts. Medicine (Baltimore). 1983;62:170-7.
7. Espersen F, Frimodt-Moller N. Staphylococcus aureus endocarditis. A review of 119 cases. Arch Intern Med. 1986;146:1118-21.
8. Wilson R, Hamburger M. Fifteen years' experience with Staphylococcus septicemia in a large city hospital: analysis of fifty-five cases in the Cincinnati General Hospital 1940 to 1954. Am J Med. 1957;22:437-57.
9. Watanakunakorn C, Baird IM. Staphylococcus aureus bacteremia and endocarditis associated with a removable infected intravenous device. Am J Med. 1977;63:253-6.
10. Shah M, Watanakunakorn C. Changing patterns of Staphylococcus aureus bacteremia. Am J Med Sci. 1979;278:115-21.
11. Cooper G, Platt R. Staphylococcus aureus bacteremia in diabetic patients. Endocarditis and mortality. Am J Med. 1982;73:658-62.
12. Libman H, Arbeit RD. Complications associated with Staphylococcus aureus bacteremia. Arch Intern Med. 1984;144:541-5.
13. Mylotte JM, McDermott C, Spooner JA. Prospective study of 114 consecutive episodes of Staphylococcus aureus bacteremia. Rev Infect Dis. 1987; 9:891-907.
14. Ehni WF, Reller LB. Short-course therapy for catheter-associated Staphylococcus aureus bacteremia. Arch Intern Med. 1989;149:533-6.
15. Dugdale DC, Ramsey PG. Staphylococcus aureus bacteremia in patients with Hickman catheters. Am J Med. 1990;89:137-41.
16. Knudsen AM, Rosdahl VT, Espersen F, Frimodt-Moller N, Skinhoj P, Bentzon MW. Catheter-related Staphylococcus aureus infections. J Hosp Infect. 1993;23:123-31.
17. Bayer AS, Tillman DB, Conception N, Guze LB. Clinical value of teichoic acid antibody titers in the diagnosis and management of the staphylococcemias. West J Med. 1980;132:294-300.
18. Malanoski GJ, Samore MH, Pefanis A, Karchmer AW. Staphylococcus aureus catheter-associated bacteremia. Minimal effective therapy and unusual infectious complications associated with arterial sheath catheters. Arch Intern Med. 1995;155:1161-6.
19. Jernigan JA, Farr BM. Short-course therapy of catheter-related Staphylococcus aureus bacteremia: a meta-analysis. Ann Intern Med. 1993;119:304-11.
20. Fowler VG Jr, Gopal AK, Marr KA, Kong L, Gottlieb GS, Sexton DJ, et al. Staphylococcus aureus bacteremia: a treatment algorithm (Abstract). Infectious Diseases Society of America, 35th Annual Meeting. San Francisco, CA: Infectious Diseases Society of America; 1997:99.
21. Erbel R, Rohmann S, Drexler M, Mohr-Kahaly S, Gerharz CD, Iversen S, et al. Improved diagnostic value of echocardiography in patients with infective endocarditis by transesophageal approach. A prospective study. Eur Heart J. 1988;9:43-53.
22. Mugge A, Daniel WG, Frank G, Lichtlen PR. Echocardiography in infective endocarditis: reassessment of prognostic implications of vegetation size determined by the transthoracic and the transesophageal approach. J Am Coll Cardiol. 1989;14:631-8.
23. Daniel WG, Mugge A, Martin RP, Lindert O, Hausmann D, Nonnast-Daniel B, et al. Improvement in the diagnosis abscesses associated with endocarditis by transesophageal echocardiography.N Engl J Med. 1991;324: 795-800.
24. Khandheria BK. Suspected bacterial endocarditis: to TEE or not to TEE [Editorial]. J Am Coll Cardiol. 1993;21:222-4.
25. Mortara LA. Bayer AS. Staphylococcus aureus bacteremia and endocarditis New diagnostic and therapeutic concepts. Infect Dis Clin North Am. 1993;7:53-68.
26. Mugge A. Echocardiographic detection of cardiac valve vegetations and prognostic implications. Infect Dis Clin North Am. 1993;7:877-98.
27. Lowry RW, Zoghbi WA, Baker WB, Wray RA, Quinones MA. Clinical impact of transesophageal echocardiography in the diagnosis and management of infective endocarditis. Am J Cardiol. 1994;73:1089-91.
28. Shapiro SM, Young E, De Guzman S, Ward J, Chiu CV, Ginzton LE, et al. Transesophageal echocardiography in diagnosis of infective endocarditis. Chest. 1994;105:377-82.
29. Daniel WG, Mugge A. Transesophageal echocardiography. N Engl J Med. 1995;332:1268-79.
30. Werner GS, Schulz R, Fuchs JB, Andreas S, Prange H, Ruschewski W, et al. Infective endocarditis in the elderly in the era of transesophageal echocardiography: clinical features and prognosis compared with younger patients. Am J Med. 1996;100:90-7.
31. Fowler VG Jr, Li J, Corey GR, Boley J, Marr KA, Gopal AK, et al. Role of echocardiography in evaluation of patients with Staphylococcus aureus bacteremia: experience in 103 patients. J Am Coll Cardiol. 1997;30:1072-8.
32. Gold MR, Siegel JE, Russell LB, Weinstein MC, eds. Cost-Effectiveness in Health and Medicine. New York: Oxford Univ Pr; 1996.
33. Sox HC Jr, Blatt MA, Higgins MC, Marton Kl. Medical Decision Making. Boston: Butterworth-Heinemann; 1988.
34. Marr KA, Sexton DJ, Conlon PJ, Corey GR, Schwab SJ, Kirkland KB. Catheter-related bacteremia and outcome of attempted catheter salvage in patients undergoing hemodialysis. Ann Intern Med. 1997;127:275-80.
35. Antoniskis A, Andersen BC, Van Volkinburg EJ, Jackson JM, Gilbert DN. Feasibility of outpatient self-administration of parenteral antibiotics. West J Med. 1978;128:203-6.
36. Durack D. Outpatient parenteral antibiotic therapy. Management of serious infections. Part II: Amenable infections and models for delivery. Endocarditis. Hosp Pract (Off Ed). 1993;28(Suppl 2):6-9.
37. Stamboulian D. Outpatient treatment of endocarditis in a clinic-based program in Argentina. Eur J Clin Microbiol Infect Dis. 1995;14:648-54.
38. Rahal JJ Jr, Chan YK, Johnson G. Relationship of staphylococcal tolerance, teichoic acid antibody, and serum bactericidal activity to therapeutic outcome in Staphylococcus aureus bacteremia. Am J Med. 1986;81:43-52.
39. Iannini PB, Crossley K. Therapy of Staphylococcus aureus bacteremia associated with a removable focus of infection. Ann Intern Med. 1976;84:558-60.
40. Le Cam B, Guivarch G, Boles JM, Garre M, Cartier F. Neurologic complications in a group of 86 bacterial endocarditis. Eur Heart J 1984; 5(Suppl C):97-100.
41. Roder BL, Wandall DA, Espersen F, Frimodt-Moller N, Skinhoj P, Rosdahl VT, Neurologic manifestations in Staphylococcus aureus endocarditis: a review of 260 bacteremic cases in nondrug addicts. Am J Med. 1997;102:379-86.
42. Korzeniowski O, Sande MA. Combination antimicrobial therapy for Staphylococcus aureus endocarditis in patients addicted to parenteral drugs and in nonaddicts: a prospective study. Ann Intern Med. 1982;97:496-503.
43. Hedstrom SA, Christensson B. Staphylococcus aureus septicaemia and endocarditis at the University Hospital in Lund 1976-1980. Scand J Infect Dis Suppl. 1983;41:38-48.
44. Pruitt AA, Rubin RH, Karchmer AW, Duncan GW. Neurologic complications of bacterial endocarditis. Medicine (Baltimore). 1978;57:329-43.
45. Jones HR Jr, Sickert RG, Geraci JE, Neurologic manifestations of bacterial endocarditis. Ann Intern Med. 1969;71:21-8.
46. Pelletier LL Jr, Petersdorf RG. Infective endocarditis: a review of 125 cases from the University of Washington Hospitals, 1963-72. Medicine (Baltimore). 1977;56:287-313.
47. Verheul HA, van den Brink RB, van Vreeland T, Moulijn AC, Düren DR, Dunning AJ. Effects of changes in management of active infective endocarditis on outcome in a 25-year period. Am J Cardiol. 1993;72:682-7.
48. Matsushita K, Kuriyama Y, Sawada T, Yamaguchi T, Nagata S, Kawazoe K, et al. Hemorrhagic and ischemic cerebrovascular complications of active infective endocarditis of native valve. Eur Neurol. 1993;33:267-74.
49. Richardson JV, Karp RB, Kirklin JW, Dismukes WE. Treatment of infective endocarditis: a 10-year comparative analysis. Circulation. 1978;58:589-97.
50. Sanabria TJ, Alpert JS, Goldberg R, Pape LA, Cheeseman SH. Increasing frequency of staphylococcal infective endocarditis. Experience at a university hospital, 1981 through 1988. Arch Intern Med. 1990;150:1305-9.
51. Austin TW, Wallace JF. Staphylococcus aureus bacteremia: a critical review of its treatment and association with infective endocarditis Infection. 1973; 1:214-7.
52. Watanakunakorn C. Staphylococcus aureus endocarditis at a community teaching hospital, 1980 to 1991. An analysis of 106 cases. Arch Intern Med. 1994;154:2330-5.
53. Koyanagi H, Matsuo K, Tezuka M, Imamura E, Endo M, Hashimoto A. Surgical treatment for infective endocarditis - decision tree for the treatment and introduction of translocation method. Jpn Circ J. 1985;49:553-61.
54. Tomos MP, Permanyer-Miralda G, Olona M, Gil M, Galve E, Almirante B, et al. Long-term complications of native valve infective endocarditis in non-addicts. A 15-year follow-up study. Ann Intern Med. 1992;117:567-72.
55. D'Agostino RS, Miller DC, Stinson EB, Mitchell RS, Oyer PE, Jamieson SW, et al. Valve replacement in patients with native valve endocarditis: what really determines operative outcome? Ann Thorac Surg. 1985;40:429-38.
56. Miller DC. Determinants of outcome in surgically treated patients with native valve endocarditis (NVE) J Card Surg. 1989;4:331-9.
57. Kimose HH, Lund O, Kromann-Hansen O. Risk factors for early and late outcome after surgical treatment of native infective endocarditis. Scand J Thorac Cardiovasc Surg. 1990;24:111-20.
58. Schulz R, Werner GS, Fuchs JB, Andreas S, Prange H, Ruschewski W, et al. Clinical outcome and echocardiographic findings of native and prosthetic valve endocarditis in the 1990's. Eur Heart J. 1996;17:281-8.
59. Soma Y, Handa S, Iwanaga S. Medical treatment or surgical intervention? A cooperative retrospective study on infective endocarditis - timing of operation. Jpn Circ J. 1991;55:799-803.
60. Eishi K, Kawazoe K, Kuriyama Y, Kitoh Y, Kawashima Y, Omae T. Surgical management of infective endocarditis associated with cerebral complications. Multi-center retrospective study in Japan. J Thorac Cardiovasc Surg. 1995;110:1745-55.
61. Dehler S, Elert O. Early and late prognosis following valve replacement for bacterial endocarditis of the native valve. Thorac Cardiovasc Surg. 1994;43: 83-9.
62. Nihoyannopoulos P, Oakley CM, Exadactylos N, Ribeiro P, Westaby S, Foale RA. Duration of symptoms and the effects of a more aggressive surgical policy: two factors affecting prognosis of infective endocarditis. Eur Heart J. 1985;6:380-90.
63. Wilson WR, Danielson GK, Giuliani ER, Washington JA 2d, Jaumin PM, Geraci JE. Cardiac valve replacement in congestive heart failure due to infective endocarditis. Mayo Clin Proc. 1979;54:223-6.
64. Croft CH, Woodward W, Elliott A, Commerford PJ, Barnard CN, Beck W. Analysis of surgical versus medical therapy in active complicated native valve infective endocarditis. Am J Cardiol 1983;51:1650-5.
65. Siddiq S, Missri J, Silverman Dl. Endocarditis in an urban hospital in the 1990s Arch Intern Med. 1996;156:2454-8.
66. Olaison L, Hogevik H, Myken P, Oden A, Alestig K. Early surgery in infective endocarditis. QJM. 1996;89:267-78.
67. Bogers AJ, van Vreeswijk H, Verbaan CJ, Kappetein AP, van Herwerden LA, Mochtar B, et al. Early surgery for active infective endocarditis improves early and late results. Thorac Cardiovasc Surg. 1991;39:284-8.
68. Larbalestier Rl, Kinchla NM, Aranki SF, Couper GS, Collins JJ Jr, Cohn LH. Acute bacterial endocarditis Optimizing surgical results. Circulation. 1992;86(5 Suppl):II68-74.
69. Fujita T, Kawazoe K, Nagata S. Infective endocarditis, present status and problems on surgical treatment. Jpn Circ J. 1985;49:562-9.
70. Symbas PN, Vlasis SE, Zacharopoulos L, Hatcher CR Jr, Arensberg D. Immediate and long-term outlook for valve replacement in acute bacterial endocarditis. Ann Surg. 1982;195:721-5.
71. Yoshida K, Yoshikawa J, Akasaka T, Hozumi T, Maeda K, Okumachi F, et al. Infective endocarditis-analysis of 116 surgically and 26 medically treated patients. Jpn Circ J. 1991;55:794-8.
72. d'Udekem Y, David TE, Feindel CM, Armstrong S, Sun Z. Long-term results of surgery for active infective endocarditis. Eur J Cardiothorac Surg. 1997;11 46-52.
73. Middlemost S, Wisenbaugh T, Meyerowitz C, Teeger S, Essop R, Skoularigis J, et al. A case for early surgery in native left-sided endocarditis complicated by heart failure: results in 203 patients. J Am Coll Cardiol. 1991;18:663-7.
74. David TE, Bos J, Christakis GT, Brofman PR, Wong D, Feindel CM. Heart valve operations in patients with active infective endocarditis. Ann Thorac Surg. 1990;49:701-5.
75. Finkelstein R, Sobel JD, Nagler A, Merzbach D. Staphylococcus aureus bacteremia and endocarditis comparison of nosocomial and community-acquired infection. J Med. 1984;15:193-211.
76. Julander I. Unfavourable prognostic factors in Staphylococcus aureus septicemia and endocarditis. Scand J Infect Dis. 1985;17:179-87.
77. Bryan CS, Kirkhart B, Brenner ER. Staphylococcal bacteremia: current patterns in nonuniversity hospitals. South Med J. 1984;77:693-96.
78. Rajashekaraiah KR, Rice T, Rao VS, Marsh D, Ramakrishna B, Kallick CA. Clinical significance of tolerant strains of Staphylococcus aureus in patients with endocarditis. Ann Intern Med. 1980;93:796-801.
79. Nolan CM, Beaty HN. Staphylococcus aureus bacteremia. Current clinical patterns. Am J Med. 1976;60:495-500.
80. Daniel WG, Erbel R, Kasper W, Visser CA, Engberding R, Sutherland GR, et al. Safety of transesophageal echocardiography. A multicenter survey of 10,419 examinations. Circulation. 1991;83:817-21.
81. Roberts GW, Holmes MD, Staugas RE, Day RA, Finlay CF, Pitcher A. Peripheral intravenous line survival and phlebitis prevention in patients receiving intravenous antibiotics: heparin/hydrocortisone versus in-line filters. Ann Pharmacother. 1994;28:11-6.
82. Bureau of the Census. Statistical Abstract of the United States 116th ed. Washington, DC: U.S. Department of Commerce, Bureau of the Census; 1996.
83. Lew EA, Gajewski J, eds. Medical Risks: Trends in Mortality by Age and Time Elapsed. v 2. New York: Praeger; 1990.
84. Dennis MS, Burn JP, Sandercock PA, Bamford JM, Wade DT, Warlow CP. Long-term survival after first-ever stroke: the Oxfordshire Community Stroke Project. Stroke. 1993;24:796-800.
85. Delahaye F, Ecochard R, de Gevigney G, Barjhoux C, Malquarti V, Saradarian W, et al. The long term prognosis of infective endocarditis. Eur Heart J. 1995;16(Suppl B):48-53.
86. Abdelnoor M, Nitter-Hauge S. Trettli S. Relative survival of patients after heart valve replacement. Eur Heart J. 1990;11:23-8.
87. Bureau of Labor Statistics. Consumer indexes. Public-use data file and documentation. http://www.bls.gov/cpihome.htm. Accessed January 1998.
88. Practice Management Information Corporation (PMIC). Physician Fees. Los Angeles: Practice Management Information Corporation (PMIC); 1998.
89. Gage BF, Cardinalli AB, Albers GW, Owens DK. Cost-effectiveness of warfarin and aspirin for prophylaxis of stroke in patients with nonvalvular atrial fibrillation. JAMA. 1995;274:1839-45.
90. Eckman MH, Levine HJ, Pauker SG. Decision analytic and cost-effectiveness issues concerning anticoagulant prophylaxis in heart disease. Chest. 1992;102(4 Suppl):5385-495.
91. Bureau of the Census. Statistical Abstract of the United States. 117th ed. Washington, DC: U.S. Department of Commerce, Bureau of the Census; 1997.
92. Revicki DA. Relationship between health state utility and psychometric health status measures. Med Care. 1992;30(5 Suppl):MS274-82.
93. Fryback DG. Dasbach EJ, Klein R, Klein BE, Dorn N, Peterson K. et al. The Beaver Dam Health Outcomes Study: initial catalog of health-state quality factors. Med Decis Making. 1993;13:89-102.
94. Mathias SD, Bates MM, Pasta DJ, Cisternas MG, Feeny D, Patrick DL. Use of the Health Utilities Index with stroke patients and their caregivers. Stroke. 1997;28:1888-94.
95. Lipscomb J, Weinstein MC, Torrance GW. Time preference. In: Gold MR, Siegel JE, Russell LB, Weinstein MC, eds. Cost-Effectiveness in Health and Medicine. New York: Oxford Univ Pr; 1996.
96. Luce BR, Manning WG, Siegel JE, Lipscomb J. Estimating costs in cost-effectiveness analysis. In: Gold MR, Siegel JE, Russell LB, Weinstein MC, eds. Cost-Effectiveness in Health and Medicine. New York: Oxford Univ Pr; 1996.
97. Mylotte JM, McDermott C. Staphylococcus aureus bacteremia caused by infected intravenous catheters. Am J Infect Control. 1987;15:1-6.
98. Lautenschlager S, Herzog C, Zimmerli W. Course and outcome of bacteremia Staphylococcus aureus: evaluation of different clinical case definitions. Clin Infect Dis. 1993;16:567-73.
99. Beck JR, Kassirer JP, Pauker SG. A convenient approximation of life expectancy (the "DEALE"). I. Validation of the method. Am J Med. 1982; 73:883-8.
100. Beck JR, Pauker SG, Gottlieb JE, Klein K, Kassirer JP. A convenient approximation of life expectancy (the "DEALE"). II. Use in medical decision making. Am J Med. 1982;73:889-97.
101. Torrance GW, Feeny D. Utilities and quality-adjusted life years. Int J Technol Assess Health Care. 1989;5:559-75.
102. Durand-Zaleski I, Zaleski S. DEALE-ing and discounting: a simple way to compute the accrued costs of preventive strategies. Med Decis Making. 1994;14:98-103.
103. Eckman MH, Greenfield S, Mackey WC, Wong JB, Kaplan S, Sullivan L, et al. Foot infections in diabetic patients. Decision and cost-effectiveness analyses. JAMA. 1995;273:712-20.
104. Weinstein MC, Stason WB. Cost-effectiveness of coronary artery bypass surgery. Circulation. 1982;66(5 Pt 2):III56-66.
105. Eisenstaedt RS, Getzen TE. Screening blood donors for human immuno-deficiency virus antibody: cost-benefit analysis. Am J Public Health. 1988;78: 450-4.
106. Hornberger JC, Redelmeier DA, Peterson J. Variability among methods to assess patients' well-being and consequent effect on a cost-effectiveness analysis. J Clin Epidemiol. 1992;45:505-12.
107. Pearson ML. Guideline for prevention of intravascular device-related infections. Part I. Intravascular device-related infections: an overview. The Hospital Infection Control Practices Advisory Committee. Am J Infect Control. 1996;24:262-277.
108. Weinstein MP, Towns ML, Quartey SM, Mirrett S, Reimer LG, Parmigiani G, et al. The clinical significance of positive blood cultures in the 1990s: a prospective comprehensive evaluation of the microbiology, epidemiology, and outcome of bacteremia and fungemia in adults. Clin Infect Dis. 1997;24:584-602.